retatrutide weight loss trials UK 2026: Phase 3 Results Eli Lilly's Phase 3 clinical
Description
Result: 30% higher osteoporosis risk
Methods Blood was drawn from 24 subjects (14 male, 10 female, age: 50.77.36years, BMI: 26.643.38kg/m2, GHbA1c: 7.000.74%) with drug-nave T2D at 0 and 120min following a standard mixed meal for the measurements of active GLP-1, NO and NOS
(Pilot study: Obesity Pillars)
Backed by science
Peak results, including significant weight loss, are typically observed between four and six months, with the most dramatic changes happening during the early months
The surprising science and sobering risks revealed.
